



(51) International Patent Classification:
C07K 16/28 (2006.01) C07K 16/30 (2006.01)

(21) International Application Number:
PCT/EP2017/052212

(22) International Filing Date:
2 February 2017 (02.02.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/290,861 3 February 2016 (03.02.2016) US

(71) Applicant: AMGEN RESEARCH (MUNICH) GMBH
[DE/DE]; Staffelseestrasse 2, 81477 Munich (DE).

(72) Inventors: RAUM, Tobias; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). MUENZ, Markus; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). BROZY, Johannes; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). KUFER, Peter; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). HOFFMANN, Patrick; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). FRIEDRICH, Matthias; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). RATTEL, Benno; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). BOGNER, Pamela; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). WOLF, Andreas; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). POMPE, Cornelius; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE).

(74) Agents: WEINZIERL, Gerhard et al.; Schiweck Weinzierl Koch, European Patent Attorneys, Landsberger Strasse 98, 80339 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS

(57) Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to a target cell surface antigen, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3e chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

